To read the full story, subscribe or sign in.

Takeda bags ex-U.S. rights to Tigenix cell therapy for Crohn's disease in $432M deal

July 6, 2016

DUBLIN – Shares in Tigenix NV gained 23 percent Tuesday on news of a sizeable ex-U.S. deal with Takeda Pharmaceutical Co. Ltd. for its allogeneic cell therapy for Crohn's disease, Cx601, which is currently undergoing regulatory review in Europe.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Feb. 5, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Illustration of liver being targets with cross-hairs

Study identifies CAND1 as therapeutic target in hepatoblastoma

BioWorld Science

Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...

Serotonin receptor modulators for the treatment of OUD

BioWorld Science

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...